Clinical impact of MYD88 mutations in chronic lymphocytic leukemia
Alejandra Martínez‐Trillos, Alba Navarro, Marta Aymerich, Julio Delgado, Armando López‐Guillermo, Elı́as Campo, Neus Villamor
Abstract
Alejandra Martínez‐Trillos, Alba Navarro, Marta Aymerich, Julio Delgado, Armando López‐Guillermo, Elı́as Campo, Neus Villamor
Abstract
To the editor: We have read with interest the letter by Baliakas et al[1][1] on the impact of MYD88 mutation in IGHV mutated (M-IGHV) chronic lymphocytic leukemia (CLL) patients. They reported a frequency of MYD88 -mutated patients of 4% in a series of 558 M-IGHV CLL, and found that M-IGHV CLL
OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
To the editor: We have read with interest the letter by Baliakas et al[1][1] on the impact of MYD88 mutation in IGHV mutated (M-IGHV) chronic lymphocytic leukemia (CLL) patients. They reported a frequency of MYD88 -mutated patients of 4% in a series of 558 M-IGHV CLL, and found that M-IGHV CLL
Key concepts: IGHV@, Chronic lymphocytic leukemia, Mutation, Leukemia, Cancer research, Biology, Immunology, Medicine